In a retrospective cohort of T2DM patients, those taking GLP-1 drugs had less peri-implant marginal bone loss at one year compared with insulin and metformin users, though no statistically significant difference remained at two years [142]. The gene discussed is INS; the disease is type 2 diabetes mellitus.